UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Learn which fund family offers the best Sharpe ratio indices and why it matters for risk-adjusted performance. Compare funds to identify strong performers.
28,055 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
When a company's chief financial officer sells stock, investors rightly pause. This article breaks down what the sale...
U.S. equities climbed on Friday as top performing stocks led a broad rally, with technology and energy names pushing ...
Micron Technology surprised markets with a standout quarter, sending its stock higher and helping steady a volatile A...
Ethereum nears $2,300 as a wave of large holders sells aggressively, yet a broader crypto upswing props the market an...
A rare volatility split signals risk concentrated in tech names. Analysts caution that this is a warning, not a crash...
Stocks reversed a sharp rally as fear returned to the market. The S&P 500’s latest surge gave way overnight, with fut...
Anthropic reports that the Trump administration has removed major usage restrictions on Claude Fable 5 and Mythos 5. ...
Policymakers are weighing tax shifts that could touch luxury spending by the ultra-wealthy. Investors watch designer ...
Palantir posted solid Q1 2026 growth, but the stock fell as investors priced in a valuation reset and AI competition....
As data suggests inflation remains stubborn and yields stay elevated, investors confront the reality that trump wants...
Global markets sold off after leaders offered little concrete trade progress. Investors warn that day one of talks ma...